A dad had no idea that an incurable disease was 'eating away' at his bones, dismissing his symptoms as back pain. Then he ...

Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean ...

Paul, from Stoke Newington, north London, managed his pain with heat packs and pain relief, but in October 2024 he stubbed ...

Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

Paul Angliss, 62, initially dismissed his severe back pain as general wear and tear, even enduring a painful ascent of Mount ...

GC Cell announced on the 29th that it has signed a contract with China's Nanjing IASO Biotechnology (IASO Bio) for the ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company is ...

The monarchE trial's primary overall survival (OS) analysis presented at ESMO 2025 confirms that 2 years of ...

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...